Zealand Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Zealand Pharma has a total shareholder equity of DKK8.9B and total debt of DKK281.0M, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are DKK9.6B and DKK746.7M respectively.
Key information
3.2%
Debt to equity ratio
DKK 280.99m
Debt
| Interest coverage ratio | n/a |
| Cash | DKK 8.48b |
| Equity | DKK 8.88b |
| Total liabilities | DKK 746.69m |
| Total assets | DKK 9.63b |
Recent financial health updates
Recent updates
Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher
Nov 09
Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt
Oct 01Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Financial Position Analysis
Short Term Liabilities: ZEAL's short term assets (DKK8.7B) exceed its short term liabilities (DKK245.6M).
Long Term Liabilities: ZEAL's short term assets (DKK8.7B) exceed its long term liabilities (DKK501.1M).
Debt to Equity History and Analysis
Debt Level: ZEAL has more cash than its total debt.
Reducing Debt: ZEAL's debt to equity ratio has increased from 0% to 3.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZEAL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZEAL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:53 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kerry Holford | Berenberg |
| Laura Hindley | Berenberg |
| Charlie Haywood | BofA Global Research |